Catalyst
Slingshot members are tracking this event:
Immunomedics (IMMU) Reports Interim Phase 2 Data Evaluating IMMU-132 in Triple Negative Breast Cancer (TNBC)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| IMMU |
|
|
||||
Additional Information
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 04, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2 Data, Immu-132, Triple Negative Breast Cancer, Patients With Prior Therapy
